Prevention of Pneumococcal Disease in Mice Immunized with Conserved Surface-Accessible Proteins

Infection and Immunity

Volumn 72, Issue 5, 2004, Pages 2659-2670

  Hamel, Josée ^a   Charland, Nathalie ^a   Pineau, Isabelle ^a,b   Ouellet, Catherine ^a   Rioux, Stéphane ^a   Martin, Denis ^a   Brodeur, Bernard R ^a  

^a Université Laval   (Canada)

^b LAVAL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CHIMERIC PROTEIN; PROTEIN BVH 3; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ANIMAL MODEL; ANTIBODY SPECIFICITY; ANTIGENICITY; ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; DRUG TARGETING; GENE LIBRARY; HUMORAL IMMUNITY; IMMUNITY; IMMUNIZATION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN TARGETING; SEQUENCE ANALYSIS; SEQUENCE HOMOLOGY; SEROTYPE; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE; VACCINE PRODUCTION;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; CONSERVED SEQUENCE; EPITOPES; GENES, BACTERIAL; HUMANS; IMMUNIZATION; IMMUNIZATION, PASSIVE; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; PNEUMONIA, PNEUMOCOCCAL; RECOMBINANT PROTEINS; SEPSIS; SEQUENCE HOMOLOGY, AMINO ACID; SEROTYPING; STREPTOCOCCUS PNEUMONIAE;

EID: 2142655010     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/IAI.72.5.2659-2670.2004     Document Type: Article

References (31)

1. Adamou, J. E., J. H. Heinrichs, A. L. Erwin, W. Walsh, T. Gayle, M. Dormitzer, R. Dagan, Y. A. Brewah, P. Barren, R. Lathigra, S. Langermann, S. Koenig, and S. Johnson. 2001. Identification and characterization of a novel family of pneumococcal proteins that are protective against sepsis. Infect. Immun. 69:949-958.
2. Alonso De Velasco, E., A. F. Verheul, J. Verhoef, and H. Snippe. 1995. Streptococcus pneumoniae: virulence factors, pathogenesis, and vaccines. Microbiol. Rev. 59:591-603.
3. Black, S., H. Shinefield, B. Fireman, E. Lewis, P. Ray, J. R. Hansen, L. Elvin, K. M. Ensor, J. Hackell, G. Siber, F. Malinoski, D. Madore, I. Chang, R. Kohberger, W. Watson, R. Austrian, and K. Edwards. 2000. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Pediatr. Infect. Dis. J. 19:187-195.
4. Briles, D. E., M. Nahm, K. Schroer, J. Davie, P. Baker, J. Kearney, and R. Barletta. 1981. Antiphosphocholine antibodies found in normal mouse serum are protective against intravenous infection with type 3 Streptococcus pneumoniae. J. Exp. Med. 153:694-705.
5. Brodeur, B. R., M. Boyer, I. Charlebois, J. Hamel, F. C. Couture, C. Rioux, and D. Martin. 2000. Identification of group B streptococcal Sip protein, which elicits cross-protective immunity. Infect. Immun. 68:5610-5618.
6. Dagan, R., N. Givon-Lavi, O. Zamir, M. Sikuler-Cohen, L. Guy, J. Janco, P. Yagupsky, and D. Fraser. 2002. Reduction of nasopharyngeal carriage of Streptococcus pneumoniae after administration of a 9-valent pneumococcal conjugate vaccine to toddlers attending day care centers. J. Infect. Dis. 185:927-936.
7. Eskola, J., T. Kilpi, A. Palmu, J. Jokinen, J. Haapakoski, E. Herva, A. Takala, H. Käyhty, P. Karma, R. Kohberger, G. Siber, and P. H. Mäkelä. 2001. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N. Engl. J. Med. 344:403-409.
8. Feikin, D. R., A. Schichat, M. Kolczak, N. L. Barrett, L. H. Harrison, L. Lefkowitz, A. McGeer, M. M. Farley, D. J. Viigia, C. Lexau, K. R. Stefonek. J. E. Patterson, and J. H. Jorgensen. 2000. Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995-1997. Am. J. Public Health 90:223-229.
9. George, H. J., H. J. Watson, D. F. Harbrecht, and W. J. DeLorbe. 1987. A bacteriophage lambda c1857 cassette controls lambda PL expression vectors at physiologic temperature. Bio/Technology 5:600-603.
10. Gosink, K. K., E. R. Mann, C. Guglielmo, E. I. Tuomanen, and H. R. Masure. 2000. Role of novel choline binding proteins in virulence of Streptococcus pneumoniae. Infect. Immun. 68:5690-5695.
11. Hausdorff, W. P., J. Bryant, C. Kloek, P. R. Paradiso, and G. Siher. 2000. The contribution of specific pneumococcal serogroups to different disease manifestations: implications for conjugate vaccine formulation and use, part II. Clin. Infect. Dis. 30:122-140.
12. Hausdorff, W. P., J. Bryant, P. R. Paradiso, and G. R. Siber. 2000. Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I. Clin. Infect. Dis. 30:100-121.
13. Hayashi, S., and H. C. Wu. 1990. Lipoproteins in bacteria. J. Bioenerg. Biomembr. 22:451-471.
14. Jayarao, B. M., J. J. Dore, Jr., G. A. Baumbach, K. R. Matthews, and S. P. Oliver. 1991. Differentiation of Streptococcus uberis from Streptococcus parauberis by polymerase chain reaction and restriction fragment length polymorphism analysis of 16S ribosomal DNA. J. Clin Microbiol. 29:2774-2778.
15. Kilpi, T., H. Åhman, J. Jokinen, K. S. Lankinen, A. Palmu, H. Savolainen, M. Grönholm, M. Leinonen, T. Hovi, J. Eskola, H. Käyhty, N. Bohidar, J. C. Sadoff, P. H. Mäkelä, et al. 2003. Protective efficacy of a second pneumococcal conjugate vaccine against pneumococcal acute otitis media in infants and children: randomized, controlled trial of a 7-valent pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine in 1666 children. Clin. Infect. Dis. 37:1155-1164.
16. Lee, L. H., C.-J. Lee, and C. E. Frasch. 2002. Development and evaluation of pneumococcal conjugate vaccines: clinical trials and control tests. Crit. Rev. Microbiol. 28:27-41.
17. Martin, D., N. Cadieux, J. Hamel, and B. R. Brodeur. 1997 Highly conserved Neisseria meningitidis surface protein confers protection against experimental infection. J. Exp. Med. 185:1173-1183.
18. Mbelle, N., R. E. Huebner, A. D. Wasas, A. Kimura, I. Chang, and K. P. Klugman. 1999. Immunogenicity and impact on nasopharyngeal carriage of a nonavalent pneumococcal conjugate vaccine. J. Infect. Dis. 180:1171-1176.
19. McEllistrem, M. C., J. Adams, E. O. Mason, and E. R. Wald. 2003. Epidemiology of acute otitis media caused by Streptococcus pneumoniae before and after licensure of the 7-valent pneumococcal protein conjugate vaccine. J. Infect. Dis. 188:1679-1684.
20. McGee, L., L. McDougal, J. Zhou, B. G. Spratt, F. C. Tenover, R. George, R. Hakenbeek, W. Hryniewicz, J. C. Lefevre, A. Tomasz, and K. P. Klugman. 2001. Nomenclature of major antimicrobial-resistant clones of Streptococcus pneumoniae defined by the pneumococcal molecular epidemiology network. J. Clin. Microbiol. 39:2565-2571.
21. Nielsen, H., J. Engelbrecht, S. Brunak, and G. von Heijne. 1997. Identification of prokaryotic and eukaryotic signal peptides and prediction of their cleavage sites. Protein Eng. 10:1-6.
22. Obaro, S. K., R. A. Adegbola, W. A. Banya, and B. M. Greenwood. 1996. Carriage of pneumococci after pneumococcal vaccination. Lancet 348:271-272.
23. Panina, E. M., A. A. Mironov, and M. S. Gelfand. 2003. Comparative genomics of bacterial zinc regulons: enhanced ion transport, pathogenesis, and rearrangement of ribosomal proteins. Proc. Natl. Acad. Sci. USA 100:9912-9917.
24. Paton, J. C. 1998. Novel pneumococcal surface proteins: role in virulence and vaccine potential. Trends Microbiol. 6:85-47.
25. Powers, D. C., E. L. Anderson, K. Lottenbach, and C. M. Mink. 1996. Reactogenicity and immunogenicity of a protein-conjugated pneumococcal oligosaccharide vaccine in older adults. J. Infect. Dis. 173:1014-1018.
26. Rapola, S., V. Jantti, R. Haikala, R. Syrjanen, G. M. Carlone, J. S. Sampson, D. E. Briles, J. C. Paton, A. K. Takala, T. M. Kilpi, and H. Käyhty, 2000. Natural development of antibodies to pneumococcal surface protein A, pneumococcal surface adhesin A, and pneumolysin in relation to pneumococcal carriage and acute otitis media. J. Infect. Dis. 182:1146-1152.
27. Shelly, M. A., H. Jacoby, G. J. Riley, B. T. Graves, M. Pichichero, and J. J. Treanor. 1997. Comparison of pneumococcal polysaccharide and CRM197-conjugated pneumococcal oligosaccharide vaccines in young and elderly adults. Infect. Immun. 65:242-247.
28. Stein, K. E. 1992. Thymus-independent and thymus-dependent responses to polysaccharide antigens. J. Infect. Dis. 165:S49-S52.
29. Tang, D. C., M. DeVit, and S. A. Johnston. 1992. Genetic immunization is a simple method for eliciting an immune response. Nature 356:152-154.
30. Tettelin, H., K. E. Nelson, I. T. Paulsen, J. A. Eisen, T. D. Read, S. Peterson, J. Heidelberg, R. T. DeBoy, D. H. Haft, R. J. Dodson, A. S. Durkin, M. Gwinn, J. F. Kolonay, W. C. Nelson, J. D. Peterson, L. A. Umayam, O. White, S. L. Salzberg, M. R. Lewis, D. Radune, E. Holtzapple, H. Khouri, A. M. Wolf, T. R. Utterback, C. L. Hansen, L. A. McDonald, T. V. Feldblyum, S. Angiuoli, T. Dickinson, E. K. Hickey, I. E. Holt, B. J. Loftus, F. Yang, H. O. Smith, J. C. Venter, B. A. Dougherty, D. A. Morrison, S. K. Hollingshead, and C. M. Fraser. 2001. Complete genome sequence of a virulent isolate of Streptococcus pneumoniae. Science 293:498-506.
31. Zhang, Y., A. W. Masi, V. Barniak, K. Mountzouros, M. K. Hostetter, and B. A. Green. 2001. Recombinant PhpA protein, a unique histidine motif-containing protein from Streptococcus pneumoniae, protects mice against intranasal pneumococcal challenge. Infect. Immun. 69:3827-3836.